Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 325,538,624
  • Shares Outstanding, K 2,720,530
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.74
  • Price/Sales 4.50
  • Price/Book 4.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
110.76 +8.04%
on 01/25/17
119.89 -0.19%
on 02/21/17
+5.51 (+4.83%)
since 01/20/17
3-Month
109.32 +9.46%
on 12/07/16
119.89 -0.19%
on 02/21/17
+4.66 (+4.05%)
since 11/21/16
52-Week
102.97 +16.21%
on 02/24/16
126.07 -5.08%
on 07/20/16
+15.50 (+14.88%)
since 02/19/16

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

AZN : 29.01 (-0.51%)
MRK : 65.48 (+0.14%)
JNJ : 119.66 (+0.67%)
AGN : 247.16 (-0.08%)
VRX : 16.40 (+2.24%)
Geron (GERN) Q4 Earnings: What's in Store for the Stock?

Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.

EXAS : 22.41 (+12.56%)
JNJ : 119.66 (+0.67%)
GERN : 2.20 (-3.51%)
PCRX : 44.15 (+1.03%)
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

JNJ : 119.66 (+0.67%)
ABBV : 61.83 (+0.10%)
AMGN : 173.14 (-0.09%)
PFE : 33.62 (unch)
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ

The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.

AZN : 29.01 (-0.51%)
JNJ : 119.66 (+0.67%)
MRK : 65.48 (+0.14%)
LLY : 80.36 (-0.04%)
AGN : 247.16 (-0.08%)
VRX : 16.40 (+2.24%)
BMY : 54.78 (+0.35%)
PhotoSonix Medical appoints former NeoStrata CEO Mark D. Steele to Board of Directors

PhotoSonix Medical, Inc. a medical technology company transforming the treatment of acne, announced that Mark D. Steele has joined the Company's Board of Directors. Mr. Steele joins a distinguished Board...

JNJ : 119.66 (+0.67%)
PG : 91.67 (+0.64%)
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback

Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.

AZN : 29.01 (-0.51%)
JNJ : 119.66 (+0.67%)
MRK : 65.48 (+0.14%)
LLY : 80.36 (-0.04%)
NVS : 77.04 (-0.21%)
AMGN : 173.14 (-0.09%)
BIIB : 286.90 (-0.71%)
Johnson & Johnson publishes prospectus for Actelion tender offer

Actelion Pharmaceuticals Ltd / Johnson & Johnson publishes prospectus for Actelion tender offer . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content...

ALIOF : 267.0000 (-0.37%)
JNJ : 119.66 (+0.67%)
Johnson & Johnson Publishes Prospectus For Actelion Tender Offer

Today Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson (NYSE:JNJ), has published the Offer Prospectus for its previously announced all-cash tender offer to acquire all of the outstanding shares...

ALIOF : 267.0000 (-0.37%)
JNJ : 119.66 (+0.67%)
Europe Cosmeceutical Market Outlook 2022

Cosmeceutical industry has revolutionised revolutionized the cosmetic and personal care industry owing to the ability of its products that resolves imperfection. Rising consumer consciousness on the appearance...

JNJ : 119.66 (+0.67%)
PG : 91.67 (+0.64%)
Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip

Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy....

JNJ : 119.66 (+0.67%)
MRK : 65.48 (+0.14%)
LLY : 80.36 (-0.04%)
PFE : 33.62 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Support & Resistance

2nd Resistance Point 120.86
1st Resistance Point 120.26
Last Price 119.66
1st Support Level 118.69
2nd Support Level 117.72

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.